New Real-World Data Highlight The Clinical Benefits Of Ultrafiltration Therapy With Hematocrit Monitoring For Pediatric Patients
Portfolio Pulse from Benzinga Newsdesk
Nuwellis, Inc. (NASDAQ:NUWE) announced new real-world data showing positive responses in pediatric patients with fluid overload to its Aquadex ultrafiltration therapy with continuous hematocrit monitoring. The study, published in Pediatric Nephrology, demonstrated successful treatment without complications. The therapy is FDA-cleared for use in adults and pediatric patients weighing 20 kg or more. Nuwellis emphasizes the importance of managing fluid overload, which is linked to increased mortality in pediatric patients.
November 28, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nuwellis' Aquadex therapy shows positive outcomes in treating pediatric fluid overload, which may increase demand and usage, potentially impacting revenues positively.
The positive real-world data and the publication in a reputable journal provide strong evidence of the efficacy of Nuwellis' Aquadex therapy. This could lead to increased adoption of the therapy in pediatric care, potentially driving up demand for the product and positively impacting the company's revenues. Given the FDA clearance for both adult and pediatric use, the potential market for Aquadex is broad, which could be a significant factor for growth. The link between fluid overload and increased mortality in pediatric patients underscores the importance of effective treatments, which could further drive the relevance and demand for Aquadex.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100